[go: up one dir, main page]

MX2019005309A - Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. - Google Patents

Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.

Info

Publication number
MX2019005309A
MX2019005309A MX2019005309A MX2019005309A MX2019005309A MX 2019005309 A MX2019005309 A MX 2019005309A MX 2019005309 A MX2019005309 A MX 2019005309A MX 2019005309 A MX2019005309 A MX 2019005309A MX 2019005309 A MX2019005309 A MX 2019005309A
Authority
MX
Mexico
Prior art keywords
combination
inhibitors
point
therapeutic use
immune check
Prior art date
Application number
MX2019005309A
Other languages
English (en)
Inventor
Caterina Turco Maria
De Laurenzi Vincenzo
Marzullo Liberato
Rosati Alessandra
Original Assignee
Biouniversa Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biouniversa Srl filed Critical Biouniversa Srl
Publication of MX2019005309A publication Critical patent/MX2019005309A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una combinación que comprende anticuerpos anti-BAG3 e inhibidores del punto de control inmunitario, a una formulación farmacéutica que comprende dicha combinación, opcionalmente con un excipiente farmacéuticamente aceptable, y a su uso en el tratamiento de enfermedades neoplásicas.
MX2019005309A 2016-11-07 2017-11-06 Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico. MX2019005309A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102016000111877A IT201600111877A1 (it) 2016-11-07 2016-11-07 Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use
PCT/EP2017/078264 WO2018083282A1 (en) 2016-11-07 2017-11-06 Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use

Publications (1)

Publication Number Publication Date
MX2019005309A true MX2019005309A (es) 2019-10-09

Family

ID=58609718

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005309A MX2019005309A (es) 2016-11-07 2017-11-06 Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.

Country Status (12)

Country Link
US (1) US20190263911A1 (es)
EP (1) EP3535296A1 (es)
JP (1) JP2020500179A (es)
KR (1) KR20190072599A (es)
CN (1) CN109923127A (es)
AU (1) AU2017352553A1 (es)
BR (1) BR112019009029A2 (es)
CA (1) CA3042992A1 (es)
IL (1) IL266116A (es)
IT (1) IT201600111877A1 (es)
MX (1) MX2019005309A (es)
WO (1) WO2018083282A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3946380A4 (en) * 2019-04-01 2022-12-21 Houn Simon Hsia COMPOSITIONS AND METHODS FOR IMMUNO-CANCER THERAPY
WO2021140173A1 (en) 2020-01-10 2021-07-15 Biouniversa S.R.L. Methods and uses for treating fibrotic solid tumors with bags inhibitors
WO2021214905A1 (ja) * 2020-04-22 2021-10-28 アステラス製薬株式会社 抗ヒトＦｎ１４抗体と免疫チェックポイント阻害剤を併用することにより、がんを予防又は治療する医薬組成物及び方法
EP4292596A4 (en) * 2021-02-10 2025-03-19 Curon Biopharmaceutical (Shanghai) Co., Limited METHODS AND COMBINATIONS FOR THE TREATMENT OF TUMORS
CN121285576A (zh) * 2023-04-13 2026-01-06 艾迪泰克斯股份有限公司 使用抗原特异性凋亡dna免疫疗法以防止和治疗由于施用免疫检查点抑制剂而产生的副作用的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP1323733A1 (en) 2001-12-28 2003-07-02 Arturo Leone BAG3 nucleotide and protein sequences to be used in research, diagnostics and therapy for cell death-involving diseases
JP4511943B2 (ja) * 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
IT1397083B1 (it) 2009-12-04 2012-12-28 Biouniversa Srl Marcatore biochimico serico
ITMI20130403A1 (it) * 2013-03-18 2014-09-19 Biouniversa Srl Anticorpi anti-bag3 per uso terapeutico
CN111744013B (zh) * 2019-03-29 2022-07-26 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合

Also Published As

Publication number Publication date
CN109923127A (zh) 2019-06-21
KR20190072599A (ko) 2019-06-25
BR112019009029A2 (pt) 2019-08-06
IT201600111877A1 (it) 2018-05-07
AU2017352553A1 (en) 2019-05-09
IL266116A (en) 2019-06-30
EP3535296A1 (en) 2019-09-11
JP2020500179A (ja) 2020-01-09
WO2018083282A1 (en) 2018-05-11
CA3042992A1 (en) 2018-05-11
US20190263911A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
PH12018502251A1 (en) Formulations of an lsd1 inhibitor
IL275798A (en) Methods for antibody drug conjugation, purification and formulation
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MX2016014414A (es) Vacuna de peptido que comprende un peptido ras mutante y un agente quimioterapeutico.
EP3421039A4 (en) Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
IN2014MU00303A (es)
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2022006770A (es) Dispersiones solidas de bendamustina e infusion continua.
IN2013MU00711A (es)
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
HK1245131A1 (zh) 用於治疗炎症性疾病的包含十六酰胺乙醇pea和番茄红素的组合物
PH12017501979A1 (en) Pharmaceutical compound
EA201691964A1 (ru) Конъюгаты для доставки лекарственного средства для лечения устойчивой формы рака и для применения в комбинированной терапии
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
TR201719926A2 (tr) Farmasöti̇k olarak kabul edi̇lebi̇li̇r li̇tyum tuzlari ve c vi̇tami̇ni̇ i̇çeren farmasöti̇k bi̇leşi̇mler
MX2016010919A (es) 4-bencilsulfonil-2-butenonitrilo.
UA109242U (uk) Стабільна фармацевтична композиція, що містить інгібітор протеасом
IN2014MU00077A (es)
UA104615U (uk) Спосіб лікування токсокарозу